Sha'ar Menashe Mental Health Center
12
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
8.3%
1 terminated/withdrawn out of 12 trials
85.7%
-0.8% vs industry average
42%
5 trials in Phase 3/4
17%
1 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Clozapine Plasma Levels and the Relationship to the Genetic Polymorphism in Shizophrenic Patients
Role: collaborator
Baclofen as Add-On to Standard Treatment of Alcohol- Dependent Patients
Role: lead
Pregnenolone and L-theanine Augmentation in the Treatment for Schizophrenia and Schizoaffective Disorders
Role: lead
Pyridoxal Kinase Activity in Tardive Dyskinesia
Role: collaborator
Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients
Role: lead
Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia
Role: lead
Genetic Expression in Schizophrenics Treated With SSRI Augmentation: Relationship to Clinical and Cognitive Function
Role: lead
Consultations in Psychiatry Through Videoconference
Role: lead
L-Theanine in the Management of Schizophrenia
Role: lead
Pregnenolone in the Management of Schizophrenia Patients
Role: lead
ECT Schizophrenia Serotonin Study
Role: lead
Psychiatric Consultation Through Videoconference in a Primary Care Setting
Role: lead
All 12 trials loaded